That is, xCT inhibitors may exhibit anticancer properties against cancer cells with elevated GLUT1 expression in a high-glucose tumor environment, whereas glucose deprivation blocks ferroptosis-induced cell death[18,19] [Figure 2B]. The gene discussed is SLC2A1; the disease is cancer.